Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pravastatin--ocular side effects after a two year follow-up?

Behrens-Baumann W, Thiery J, Fieseler HG, Seidel D.

Lens Eye Toxic Res. 1990;7(3-4):311-8.

PMID:
2129219
2.

[Evaluation of the efficacy and safety of pravastatin in primary hypercholesterolemia].

Craveri A, Citella C, Lanfredini M, Colombo L, Bruschi R.

Boll Chim Farm. 1990 Jun;129(6):10S-15S. Italian.

PMID:
2127364
3.

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.

Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R.

Diabetes Obes Metab. 2000 Dec;2(6):355-62.

PMID:
11225965
4.
5.

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.

Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W Jr, et al.

Atherosclerosis. 1990 Nov;85(1):81-9.

PMID:
2126437
6.

Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.

Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Takeuchi I, et al.

Atherosclerosis. 1988 Aug;72(2-3):205-11.

PMID:
3145746
7.

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.

Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, Insull W Jr, Pan HY.

Atherosclerosis. 1990 Dec;85(2-3):219-27.

PMID:
2129319
8.

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.

Behrens-Baumann W, Thiery J, Wieland E, Fieseler HG, Seidel D.

Arzneimittelforschung. 1992 Aug;42(8):1023-4.

PMID:
1418074
9.

[Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].

Schwartzkopff W, Bimmermann A, Schleicher J.

Arzneimittelforschung. 1990 Dec;40(12):1322-7. German.

PMID:
2128866
10.
12.

Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin.

Schmitt C, Schmidt J, Hockwin O.

Lens Eye Toxic Res. 1990;7(3-4):631-42.

PMID:
2129220
13.

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.

Hoogerbrugge N, Mol MJ, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef AF, Birkenhäger JC.

J Intern Med. 1990 Sep;228(3):261-6.

PMID:
2119419
15.

Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.

Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.

Int J Cardiol. 2005 Oct 10;104(3):338-45.

PMID:
16186066
16.

Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.

Behrens-Baumann W, Morawietz A, Thiery J, Creutzfeldt C, Seidel D.

Lens Eye Toxic Res. 1989;6(1-2):331-7.

PMID:
2488025
17.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
18.

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.

Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group.

Diabetes Obes Metab. 2005 Jul;7(4):430-8. Erratum in: Diabetes Obes Metab. 2005 Jul;7(4):460.

PMID:
15955130
19.
20.

Supplemental Content

Support Center